SCYNEXIS Partnering with Amplity Health to Launch BrexafemmeTM

SCYNEXIS, Inc.  is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. 

FDA accepted SCYNEXIS’ New Drug Application (NDA) for oral ibrexafungerp for the treatment of vaginal yeast infections, conditionally approved the brand name Brexafemme^TM, and granted priority review with a PDUFA target action date of June 1, 2021.

SCYNEXIS is planning a U.S. Commercial launch in the second half of 2021 for the treatment of VVC (Vulvovaginal Candidiasis). SCYNEXIS estimates a large market with only one oral approved product and >18 million prescriptions annually, and U.S. peak sales of $400-600 million.

SCYNEXIS announced that it has partnered with Amplity Health, a leading global contract commercialization organization, to support the anticipated U.S. commercialization of Brexafemme.

Amplity Health offers wide-ranging capabilities such as clinical and medical outsourced teams, capabilities development, field sales solutions, insights and patient identification solutions, consulting, sourcing and recruiting, multichannel messaging, execution, and more. 

Altamont Capital Partners acquired Publicis Healthcare Solutions (PHS) from Publicis Groupe in January 2019. PHS Health Solutions began operating under the new identity of Amplity Health after the acquisition. The new corporate brand integrates a family of brands including Touchpoint, PDI and Tardis Medical.

Takeaway: SCYNEXIS will utilize Amplity’s commercial execution expertise and resources for sales force, remote engagement, training, market access and select operations services